Scotland Implements Newborn Screening for Rare Genetic Condition, First in the UK

Spinal Muscular Atrophy (SMA) is a genetic disorder characterized by progressive muscle weakness due to the degeneration of motor neurons in the spinal cord. The condition is primarily caused by a deficiency in the survival motor neuron 1 (SMN1) gene, which plays a critical role in motor neuron health and function.

Without timely intervention, SMA can significantly impact life expectancy, with severe forms of the disease potentially leading to shortened lifespans of approximately two years. However, advancements in medical treatments, including gene therapy and novel pharmacological approaches, have emerged in recent years, improving outcomes for many individuals diagnosed with this condition. These treatments can enhance motor function and increase life expectancy, underscoring the importance of early diagnosis and management.

SMA affects individuals in varying degrees, with symptoms usually manifesting in infancy or early childhood, though some forms may appear in later stages of life. As awareness of SMA grows, ongoing research continues to explore effective therapies and support for affected families.